RxDoctor Payments Data

Kevin Clearman

Family · Hattiesburg, MSNPI 1477557098

Payments from drug & device makers

$8,537in general payments, 2019–2025

Across 597 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Novo Nordisk$1K
  • AstraZeneca$739
  • Boehringer Ingelheim$484
  • Johnson & Johnson$431
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,537 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$107,050
Medicare patients
516
Services billed
3,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$57,499
MounjaroTirzepatide38$40,740
JanuviaSitagliptin Phosphate25$32,888
RybelsusSemaglutide17$23,143
FarxigaDapagliflozin Propanediol21$22,347
EliquisApixaban19$22,076
XareltoRivaroxaban11$5,867
SymbicortBudesonide/Formoterol Fumarate20$5,486
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$4,514
Rosuvastatin Calcium174$2,477
Cefdinir94$1,903
SynthroidLevothyroxine Sodium20$1,534
Albuterol Sulfate HfaAlbuterol Sulfate46$1,500
PaxlovidNirmatrelvir/Ritonavir26$1,429
Losartan Potassium107$1,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$484$57,49947 claims
Lilly USA, LLCMounjaro$386$40,74038 claims
MerckJanuvia$148$32,88825 claims
AstraZenecaFarxiga, Symbicort$739$27,83341 claims
PfizerEliquis, Paxlovid$81$23,50545 claims
Novo NordiskRybelsus$1,036$23,14317 claims
Johnson & JohnsonXarelto$431$5,86711 claims
AbbVieSynthroid$1,375$1,53420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →